TOP STORY
FDA recently approved the first over-the-counter test for HIV, providing a confidential in-home testing option for the virus that causes AIDS, with results in as little as 20 minutes. » More |
CONTINUING EDUCATION
Pharmacists need to gain insight into cultural competency to better serve the increasing racial and ethnic populations in the United States.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login. |
EDITOR’S PICK
American Psychiatric Association 2012 Annual Meeting
Clinical updates review findings on long-acting levomilnacipran in major depressive disorder, depot versus oral antipsychotics for schizophrenia. » Click here. |
FDA NEWS
FDA is alerting healthcare professionals to the possibility that a 32-mg single intravenous dose of ondansetron (Zofran, ondansetron hydrochloride, and generics) could lead to QT interval prolongation, putting patients at risk for a potentially fatal heart rhythm known as Torsades de Pointes. » More |
|
FDA has approved once-daily phentermine and topiramate extended-release (Qsymia, Vivus) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least 1 weight-related comorbidity. » More |
Clinical News
The results of a recent literature review suggest that only a high intake of vitamin D leads to a significant reduction in the risk of fracture. » More |
Survey
a) "Lock-in" programs – limiting access for high utilizers to single pharmacy and/or physician provider
b) Tighter dispensing limits on the number of units and/or prescriptions a patient can receive for controlled meds
c) Limiting coverage to only long-acting formulations with effective abuse-deterrant delivery systems
d) More broad and advanced state-based controlled prescription monitoring/surveillance systems
e) Limiting coverage of long-acting opioid prescriptions to select specialty providers
f) Other
Click here and see what your colleagues think, too.
Want to see the results of our last survey about specialty pharmacy services? Click here. |
|
Confirm your
e-newsletter subscription click here.
To ensure future delivery of email newsletters from Formulary please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff |
Digital Edition |
|
|
